Identification of novel estrogen receptor inhibitors for the treatment of hormone resistant breast cancer
Estrogen receptor alpha positive (ERα+) disease constitutes approximately 75% of all breast cancer (BCa) cases. However resistance to hormone therapy is observed in early-stage as well as in metastatic disease. Importantly, 70% of ERα+ primary tumors retain active ERα when they metastasize and, ther...
| Main Author: | |
|---|---|
| Language: | English |
| Published: |
University of British Columbia
2017
|
| Online Access: | http://hdl.handle.net/2429/61340 |